Colorado's success at attracting venture capital was demonstrated earlier this month when Boulder-based Clovis Oncology, Inc. announced an impressive $145 million in start-up funding at its company launch. Clovis is focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company is founded by former executives of Pharmion Corporation, which was acquired by Celgene Corporation in 2008 for $2.9 billion.
"We are so very pleased that the former Pharmion team has chosen to remain in the state and headquarter their new company here. With the experience behind them and the success of the business model from Pharmion, the bioscience industry and Colorado will be keeping a close, and proud, eye on this new start-up," Collar says.